Vaccination is the most effective way to prevent flu infection. Each year, several different flu strains are selected as vaccine candidates based on surveillance data of the recent isolates and the performance of the vaccines from the previous season. In recent decades, most influenza vaccines are trivalent or quadrivalent, composed of one H1N1, one H3N2, and either one or two type B viruses (Yamagata and Victoria lineage).
Sino Biological offers recombinant flu antigen products under its ProVir® viral antigen collection. The product line covers Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains of recent years. These antigens can be used to analyze vaccine-induced antibody response. In addition, Sino Biological has also developed an extensive collection of monoclonal antibodies against the flu antigens. These reagents can help facilitate relevant assay development.
